Literature DB >> 10578448

Treatment of schizophrenia and spectrum disorders: pharmacotherapy, psychosocial treatments, and neurotransmitter interactions.

H Y Meltzer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10578448

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  20 in total

Review 1.  Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?

Authors:  L Dépatie; S Lal
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

2.  Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia.

Authors:  Susana Conde-Ceide; Carlos M Martínez-Viturro; Jesús Alcázar; Pedro M Garcia-Barrantes; Hilde Lavreysen; Claire Mackie; Paige N Vinson; Jerri M Rook; Thomas M Bridges; J Scott Daniels; Anton Megens; Xavier Langlois; Wilhelmus H Drinkenburg; Abdellah Ahnaou; Colleen M Niswender; Carrie K Jones; Gregor J Macdonald; Thomas Steckler; P Jeffrey Conn; Shaun R Stauffer; José Manuel Bartolomé-Nebreda; Craig W Lindsley
Journal:  ACS Med Chem Lett       Date:  2015-05-20       Impact factor: 4.345

Review 3.  What Is the Link Between Hallucinations, Dreams, and Hypnagogic-Hypnopompic Experiences?

Authors:  Flavie Waters; Jan Dirk Blom; Thien Thanh Dang-Vu; Allan J Cheyne; Ben Alderson-Day; Peter Woodruff; Daniel Collerton
Journal:  Schizophr Bull       Date:  2016-06-29       Impact factor: 9.306

Review 4.  Progress toward positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5).

Authors:  Shaun R Stauffer
Journal:  ACS Chem Neurosci       Date:  2011-06-27       Impact factor: 4.418

5.  Discovery of novel N-substituted oxindoles as selective m1 and m4 muscarinic acetylcholine receptors partial agonists.

Authors:  Takaaki Sumiyoshi; Takeshi Enomoto; Kentaro Takai; Yoko Takahashi; Yasuko Konishi; Yoshiharu Uruno; Kengo Tojo; Atsushi Suwa; Harumi Matsuda; Tomokazu Nakako; Mutsuko Sakai; Atsushi Kitamura; Yasuaki Uematsu; Akihiko Kiyoshi
Journal:  ACS Med Chem Lett       Date:  2013-01-27       Impact factor: 4.345

6.  Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5).

Authors:  María Luz Martín-Martín; José Manuel Bartolomé-Nebreda; Susana Conde-Ceide; Sergio A Alonso de Diego; Silvia López; Carlos M Martínez-Viturro; Han Min Tong; Hilde Lavreysen; Gregor J Macdonald; Thomas Steckler; Claire Mackie; Thomas M Bridges; J Scott Daniels; Colleen M Niswender; Meredith J Noetzel; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley; Shaun R Stauffer
Journal:  Bioorg Med Chem Lett       Date:  2015-01-28       Impact factor: 2.823

7.  Directed forgetting in schizophrenia: prefrontal memory and inhibition deficits.

Authors:  Ulrich Müller; Markus Ullsperger; Eva Hammerstein; Stefan Sachweh; Thomas Becker
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-22       Impact factor: 5.270

Review 8.  Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia.

Authors:  P Jeffrey Conn; Craig W Lindsley; Carrie K Jones
Journal:  Trends Pharmacol Sci       Date:  2008-12-06       Impact factor: 14.819

9.  Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs.

Authors:  D E Adkins; K Aberg; J L McClay; J Bukszár; Z Zhao; P Jia; T S Stroup; D Perkins; J P McEvoy; J A Lieberman; P F Sullivan; E J C G van den Oord
Journal:  Mol Psychiatry       Date:  2010-03-02       Impact factor: 15.992

10.  Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia.

Authors:  Tomiki Sumiyoshi; A Roy; C-H Kim; K Jayathilake; M A Lee; C Sumiyoshi; H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2004-06-04       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.